PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Aviptadil→

Aviptadil PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
40077-57-4
Molecular formula
C147H237N43O43S
Molecular weight
3326.8 g/mol
Drug class
Vasoactive intestinal peptide (VIP) analoguepeptide VPAC-receptor agonist
Mechanism of action
A synthetic analogue of vasoactive intestinal peptide that activates VIP receptors, including VPAC1, and can promote smooth-muscle relaxation and vasoactive signalling.
Indications / reported uses
  • Used in combination with phentolamine in locally authorised intracavernosal products for erectile dysfunction; the combination and route are product-specific.

Sources: https://www.cancer.gov/publications/dictionaries/cancer-drug/def/aviptadil · https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10891

View request basketPrefer email? info@toxwriter.com
PDE / ADE derivationOEL derivationOEB / OHC banding
Assessment scope

PDE/ADE and OEL/OEB assessment

ToxWriter provides project-specific support for Aviptadil PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Aviptadil Permitted Daily Exposure (PDE) report (the Aviptadil PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Aviptadil Occupational Exposure Limit (OEL) report (the Aviptadil OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.